Anti-VEGF immunotherapy with HEBERSaVax suppresses melanoma growth and metastasis via angiogenesis blockade and enhanced T-cell infiltration
Our results demonstrate that HEBERSaVax mediates dual antitumor efficacy by simultaneously suppressing VEGF-dependent angiogenesis and promoting immune-related changes in the melanoma microenvironment. These findings support the further development of HEBERSaVax as a promising active immunotherapy for VEGF-driven advanced melanoma.
Authors
- Mónica Béquet‐Romero (ORCID: https://orcid.org/0000-0003-0351-857X)
- Alfredo Martı́nez (ORCID: https://orcid.org/0000-0003-4882-4044)
- Alexei F. Licea-Navarro (ORCID: https://orcid.org/0000-0003-4022-7405)
- Josune Garcı́a-Sanmartı́n (ORCID: https://orcid.org/0000-0003-4391-5537)
- Srdan Tadic (ORCID: https://orcid.org/0000-0001-8670-0427)
- Johanna Bernáldez-Sarabia (ORCID: https://orcid.org/0000-0003-4894-5604)
- Judit Narro-Íñiguez (ORCID: https://orcid.org/0000-0001-5336-4930)
- Isabel González-Moya (ORCID: https://orcid.org/0000-0001-7633-4769)
- Marta Ayala‐Ávila (ORCID: https://orcid.org/0000-0003-4441-4953)
- Dasha Fuentes-Morales
- Pablo Garrido (ORCID: https://orcid.org/0000-0002-5960-8569)
- Blanca J. Valdovinos-Navarro (ORCID: https://orcid.org/0000-0003-2017-9127)
- Yanelys Morera Díaz (ORCID: https://orcid.org/0000-0001-6051-5514)
- Camila Canaán-Haden
Institutions
- National Institute of Animal Science (KR)
- Centro de Ingeniería Genética y Biotecnología (CU)
- Center for Biomedical Research of La Rioja (ES)
- Centro de Investigación Científica y de Educación Superior de Ensenada (MX)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1667651
- Primary Topic
- Toxin Mechanisms and Immunotoxins
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Regional Development Fund
- Agencia Estatal de Investigación